Clene Inc. (NASDAQ: CLNN) and its wholly owned subsidiary, Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”), will attend … Continue reading →

Clene (NASDAQ: CLNN) and its wholly owned subsidiary, Clene Nanomedicine Inc., is partnering with APST Research GmbH to analyze neurofilament light chain (“NfL”) data in evaluating its drug candidate, CNM-Au8®, for ALS treatment. Based in Germany, APST operates one of the … Continue reading →

Clene (NASDAQ: CLNN) a late clinical-stage biopharmaceutical company developing treatments for neurodegenerative diseases such as ALS and MS, announced its participation in the 37th Annual Roth Conference. Management will host a virtual fireside chat on March 18, 2025, at 9:20 a.m. … Continue reading →

Clene Inc. (NASDAQ: CLNN) and its wholly owned subsidiary, Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”), and multiple sclerosis (“MS”), will … Continue reading →

Clene Inc. (NASDAQ: CLNN) and its wholly owned subsidiary, Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”), has … Continue reading →

Clene (NASDAQ: CLNN) announced that CEO Rob Etherington and CFO Morgan Brown will present at the Investor Summit Virtual on March 11, 2025. The event will provide investors with insights into the company’s latest developments and strategic outlook. To view the … Continue reading →

Clene (NASDAQ: CLNN) has entered into an agreement with Germany-based APST Research GmbH to utilize its extensive neurofilament light chain (NfL) database in FDA-recommended analyses of CNM-Au8® for treating amyotrophic lateral sclerosis (ALS). APST’s repository includes biomarker data from over 4,300 … Continue reading →

Clene (NASDAQ: CLNN) and its wholly owned subsidiary, Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”), recently received additional … Continue reading →

Clene (NASDAQ: CLNN) and its wholly owned subsidiary, Clene Nanomedicine Inc., is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”). The company … Continue reading →

Clene (NASDAQ: CLNN) and its wholly owned subsidiary, Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”), has received additional … Continue reading →